(Q40926668)

English

Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.

scientific article published on 19 May 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

multiple drug resistance

1 reference

based on heuristic

inferred from title

1 reference

ChEBI release 2020-05-28

František Štaud

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Daniela Cihalova

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Martina Ceckova

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

19 May 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

76

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

105-116

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25986678%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

https://scigraph.springernature.com/pub.10.1007/s00280-015-2772-1

0 references

ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Improving cancer chemotherapy with modulators of ABC drug transporters

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Modulators of multidrug resistance associated proteins in the management of anticancer and antimicrobial drug resistance and the treatment of inflammatory diseases

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

The challenge of exploiting ABCG2 in the clinic.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Principles of CDK regulation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Cell cycle, CDKs and cancer: a changing paradigm

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Cyclin dependent kinases in cancer: potential for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

The CDK inhibitors in cancer research and therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Multidrug resistance in cancer: role of ATP-dependent transporters

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Drug interactions in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1)

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Potent interaction of flavopiridol with MRP1

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Targeting multidrug resistance in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Utilization of membrane vesicle preparations to study drug–ABC transporter interactions

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Single agent versus combination chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2772-1

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40926668&oldid=2092726747"